Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below:
New York, NY
- Tweets 1,250
- Following 195
- Followers 14,700
- Likes 148
Join Dr. Yatham and Dr. Vieta at #ISBD2026 as they discuss the current treatment landscape, unmet needs, hypothesized disease mechanisms, emerging therapies and advances toward personalized management.
1
174
During #IMS26, Dr. Doris Hansen will present results from a Phase 1 study focused on an investigational dual-targeting CAR T cell therapy approach being evaluated in patients with relapsed/refractory multiple myeloma.
See our latest research updates: bit.ly/3UXV7gh
1
179
Join us at #IMS26 on Friday, September 25, for an oral presentation exploring the Phase 3 EXCALIBER-RRMM results.
Explore our latest hematology research updates: bit.ly/47eRgOr
1
2
221
Today at #IMS26, we're sharing Phase 3 research evaluating hematologic adverse events and infections associated with treatment, as well as health-related quality of life, in relapsed/refractory multiple myeloma.
See more on our hematology research: bit.ly/4yRSTxA
1
1
294
OUT NOW: A special 2-part episode of #DoctoRxUnscripted! Dr. Tania Small, Chris Boerner, @ariannahuff and Dr. @Neil_Iyengar explore how precision oncology & behavioral science unite to transform patient outcomes. Watch: bit.ly/3V8UTmp
1
4
235
At #IMS26 we’ll be presenting our latest updates in multiple myeloma, including advances from our protein degradation platform and research spanning our multiple myeloma portfolio and pipeline, including CAR T cell therapy.
Explore our research: bit.ly/4d0c3c2
2
185
Join us at #ENGAGE26 as Susan Scanland, a geriatric nurse practitioner, explores the unmet needs and evidence-based management of psychosis and agitation in Alzheimer’s disease. Gain practical strategies for symptom assessment, care partner engagement and shared decision-making.
1
112
Join us at #PsychCongress2026 for two Medical Innovation Theater sessions exploring the evolving understanding of schizophrenia and bipolar I disorder.
Learn more about our medical events and scientific exchange opportunities: bit.ly/3UKE01l
#OneBMS
1
195
Join us at #PsychCongress2026 as Dr. Tohen explores the diagnostic challenges in bipolar disorder, examines real-world evidence to deepen understanding of disease course, and discusses the evolving research landscape around long-term outcomes.
168
At #WCLC2026, we're sharing updates from studies evaluating an investigational bispecific in NSCLC and mesothelioma. Hear from Rajni Kannan on how scientific exchange and collaboration inform our work as we advance the bispecific research platform. bit.ly/3UVBg12 #OneBMS
1
3
7
556
As the biomarker landscape continues to evolve, comprehensive testing is an important part of identifying patients. Join us at #ECP2026 as we discuss practical considerations & emerging approaches in NSCLC diagnostics.
Explore the latest on MTAP deletion: bit.ly/4xLcWgQ
2
178
From clinical trial insights to real-world evidence, we’ll be presenting exciting updates on our immuno-oncology research across tumor types at #WCLC26.
Hear more from Pratik Thakkar and stop by our booth to connect with our team in Seoul. bit.ly/4xLIiE9
#OneBMS
2
7
271
Join us at #WCLC26 as @LuisPaz_Ares and @DrMarkAwad present the ROSETTA Lung-201 and ROSETTA Lung-202 Trial-in-Progress (TiP) posters, highlighting new data in non-small cell lung cancer. Explore our oncology research updates: bit.ly/4cBuO5p #OneBMS #BioNTech_Group
1
1
324
Join us at #PsychCongress2026 as Dr. Christoph Correll and Andrew Penn explore the evolving understanding of schizophrenia pathophysiology, describe the current treatment landscape and discuss pathways that could inform the direction of future research.
223
Join us tomorrow at #WCLC2026 for a mini-oral presentation featuring long-term PFS and OS data investigating a PD-L1xVEGF-A bispecific antibody in mesothelioma.
Explore our latest oncology research updates: bit.ly/3VaHLgx
#OneBMS #Mesothelioma #BioNTech_Group
1
229
We're working to advance research for people with homozygous MTAP deletions, a biomarker found in some solid tumors that remains underrecognized in routine testing. Explore MTAP Matters, a new resource on the latest in MTAP deletion research: bit.ly/4xpsjuy
#ECP2026
1
3
204
Hear from Shreya Mitra about one of the studies our team will present at #WCLC26 on the potential of antibody-drug conjugates (ADCs). Visit the BMS Grand Medical Library to learn more about our science. Explore our latest oncology research updates: bit.ly/3ULc6lL #OneBMS
3
211
Today’s official #WCLC2026 press program featured results from our global Phase 1 randomized dose-expansion study in previously treated EGFR-mutated non-small cell lung cancer (NSCLC). Join us for the full presentation on Sept. 14.
Learn more: bit.ly/4xPCERi
#OneBMS
228
We're investigating the role of the lysophosphatidic acid receptor 1 (LPA1) pathway to better understand the biological processes that contribute to pulmonary fibrosis. Learn more about the LPA1 pathway: bit.ly/3Ss468u #ERSCongress #PFMonth #OneBMS
1
252
Join our symposium at #ERSCongress as Dr. @Bruno_Crestani, MD, PhD, Head at Public Assistance Hospitals of Paris Bichat Claude-Bernard Hospital, explores patient and pulmonologist perspectives across IPF and PPF: bit.ly/4xOwocD
284
Join us at #ESCCongress for our Satellite Symposium and Daily Tutorials on obstructive hypertrophic cardiomyopathy (oHCM). Learn more about our expert-led sessions: bit.ly/4qEpq79
#OneBMS
184
Cancer research is advancing through multiple scientific approaches, from targeted protein degradation to ADCs and AI-enabled discovery. Learn more in this @statnews article: bit.ly/4wYrUjc #OneBMS
193
Biology-based lifestyle interventions are no longer just wellness advice. Dr. @tania_small brings together BMS CEO Chris Boerner, Thrive Global CEO @ariannahuff and cancer survivorship expert @Neil_Iyengar to make the case for change. Watch more now: bit.ly/3RjKCSY
1
3
478
We’re advancing investigational therapies in Alzheimer’s disease that aim to slow progression and help manage behavioral symptoms, working toward an improved continuum of care for patients and families: bit.ly/4vStAu5
#AAIC2026 #OneBMS
4
267
Join us tomorrow at #AAIC2026 as Dr. @Clive_Ballard explores neuropathological mechanisms linking cognitive and neuropsychiatric symptoms in Alzheimer’s disease.
Learn more: bit.ly/4hbNNX4
#OneBMS
1
4
352
Don't miss the Phase 2 ROSETTA PDAC-109 TiP poster tomorrow at #ESMOGI2026.
Stop by the poster session from 3:30 to 4:30pm CEST.
We are developing this investigational PD-L1xVEGF-A immunomodulator in collaboration with @BioNTech_Group.
#PancreaticCancer
254
Join us tomorrow at #ESMOGI2026 as Dr. Sara Lonardi presents ROSETTA CRC-203 TiP poster.
Join the poster session from 3:30 to 4:30pm CEST.
We are developing this investigational PD-L1xVEGF-A immunomodulator in collaboration with @BioNTech_Group.
#GICancer
226
Join us at #IPA2026 to hear Dr. Creese discuss clinical recognition and evidence-based management of Alzheimer’s disease psychosis and agitation, with emphasis on current and emerging therapeutic approaches. #ipacongress2026
119
Data published in @TheLancet evaluate an investigational oral therapy for the growing number of patients with relapsed/refractory #MultipleMyeloma using our CELMoD approach: bit.ly/4xLc24D #EHA2026
2
4
291
Today @ #EHA2026, catch Dr. Susan Bal’s (@SusanBal9) presentation on updated Phase 1 safety and efficacy results of an investigational GPRC5D #CART in #RRMM after 1–3 prior treatments.
Share your thoughts on how the #RRMM treatment landscape is evolving. bit.ly/4el1Dn9
1
200
A primary analysis of a BMS study presented at #EHA26 evaluates an EMA at the maximum-approved dose in patients with lower-risk MDS who are red blood cell transfusion dependent. bit.ly/4gityql
2
180
Explore how we’re advancing cell therapy, leveraging next-generation cell engineering and new approaches to expand what’s possible in hematologic malignancies: bit.ly/4onBlFx
#EHA2026 #ScienceFirsthand #OneBMS
1
150
Today at #EHA2026, Dr. Narendranath Epperla (@NEpperla) will share the results of a real-world study evaluating CD19 #CAR T cell therapy and bispecifics in 3L+ #LBCL. bit.ly/4ojIDKh
156
Don’t miss our session at #EULAR2026, where CAR T experts will discuss the emerging research in “immune reset” concept, and key considerations for B cell–targeted strategies, including patient selection in clinical trials. bit.ly/4x5irab
218
Join us at #EULAR2026, as we present new data from our translational research on the correlation between the tyrosine kinase 2 (TYK2) immune pathway and Sjögren’s disease manifestations. Learn more about immune signaling pathways: bit.ly/3PRg7mE
142
See how we’re advancing targeted protein degradation using three powerful approaches, CELMoD agents, ligand-directed degraders and degrader antibody conjugates, to drive innovation in cancer and beyond: bit.ly/43cf0AW
#ASCO26 #OneBMS
176
Join us at #ASCO26 as new Phase 3 data in triple-negative breast cancer (TNBC) is presented. Learn more: bit.ly/434KSY9
168
Today at #ASCO26, tune in for results from a large real-world study on the #CART treatment experience for 2L+ #LBCL across FACT and non-FACT centers in the United States.
Share your perspective on bringing CAR T closer to home for patients. bit.ly/4wX2P8P
1
1
177
At #ASCO26, new Phase 3 data in metastatic esophageal squamous cell carcinoma (ESCC) will be presented. Learn more: bit.ly/43AQAkD
155
Join us tomorrow at #ASCO26 as Dr. Solange Peters presents Phase 2 results from ROSETTA Lung-02. @peters_solange
Stop by or join the live stream from 1:21–1:27pm CDT. #LungCancer #BioNTech_Group
1
1
207
Join us tomorrow at #ASCO26 as Dr. Tiago Biachi de Castria presents ROSETTA CRC-203 TiP poster. @BiachiTiago
Join the poster session from 9am to 12pm CDT. #GICancer #BioNTech_Group
1
3
243
Breakthroughs in oncology are moving fast—but access is still determining who benefits from them.
On DoctoRx Unscripted, leading oncologists join Dr. Tania Small to explore what it will take to close that gap. Watch the full oncology series now: bit.ly/4tV3lkR
1
126
Nearly 70% of lung cancers are still diagnosed at an advanced stage, but science is changing what’s possible—giving some patients years of life back. Two leading oncologists join Dr. Tania Small to discuss how more patients can benefit. Watch now: bit.ly/4usEsOC
4
3,273
Melanoma incidence continues to rise, affecting diverse age groups. Early detection and awareness are vital for better outcomes.
Hear more about the realities of melanoma: bit.ly/4tM7J5M
#OneBMS #MelanomaAwarenessMonth
1
134
At #ATS2026, we're exploring the pathophysiology of #PulmonaryFibrosis, and the key role the lysophosphatidic acid (LPA-LPA1) pathway plays in epithelial cell injury, inflammation and fibrosis—all of which result in disease progression. Learn more: bit.ly/4nDzbkM #OneBMS
213
Endocannabinoids help regulate neuronal signaling. We’re exploring how inhibition of Fatty acid amide hydrolase (FAAH) and Monoacylglycerol lipase (MAGL) may impact endocannabinoid levels in conditions like Alzheimer’s disease. Learn more: bit.ly/4dbQ3u2 #OneBMS
203
Wrap up the last day of the #AACR2026 conference by stopping by the poster session to hear Dr. Jaclyn Neely’s presentation of the biomarker analyses from the RELATIVITY 104 trial.
Join the session from 9am to 12pm PST #LungCancer #NSCLC
1
1
315
Stop by the poster session tomorrow, at #AACR2026, to hear Dr. Takekazu Aoyama’s overview of the RELATIVITY 020 clinical trial, with a focus on dose safety and efficacy.
Join the session from 9am to 12pm PST. #SolidTumor
1
207
Today at #AACR2026, Dr. Igor Katsyv will present the poster Comparison of MTAP loss by IHC and MTAP homozygous deletion by NGS and DNA FISH.
Stop by the poster session from 2–5pm PST. #CancerGenomics #AssayDevelopment #AACR2026
210
Our teams are advancing targeted protein degradation leveraging three distinct modalities: CELMoD agents, ligand-directed degraders and degrader antibody conjugates. Explore how we’re driving cancer breakthroughs: bit.ly/4cplmB5
#AACR26 #ScienceFirsthand #OneBMS
1
254